Drug intelligence / Profile preview

AFA-2000

Development stage: Preclinical
Lead developer: AfaSci
Modality: Small Molecules

Overview

AFA-2000 is a preclinical small molecule drug candidate being developed by AfaSci, Inc. It functions as a modulator of G protein-coupled inwardly rectifying potassium (GIRK) channels. By directly activating these channels, the compound aims to reduce neuronal excitability, offering a potential therapeutic approach for chronic and neuropathic pain as well as sleep disorders such as insomnia. Research indicates that GIRK activation can promote non-rapid eye movement (NREM) sleep. The drug is currently in the lead optimization stage of development.

Targets

KACh (G protein–activated inwardly rectifying potassium channel)

Beyond the preview

Go deeper on AFA-2000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AFA-2000.

Explore the full profile